SCHEMBL1703588

SCHEMBL1703588

CNC(=O)C(F)F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10153710 0.78
SCHEMBL6778465 0.75
SCHEMBL15993879 0.75
SCHEMBL15994076 0.75
Hydrochloric Acid SCHEMBL27634675 0.75
SCHEMBL24050459 0.73
SCHEMBL8709678 0.71
SCHEMBL4954303 0.71
SCHEMBL15993794 0.71
SCHEMBL10050949 0.71 MAPT (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117730083-A Pyrimidine compounds as MAP4K1 inhibitors 格兰马克专业公司 2024-03-19 CN claimed
CN-117500507-A Phosphorus derivatives as novel SOS1 inhibitors 拜耳公司 2024-02-02 CN claimed
CN-117015548-A Synthetic ursolic acid derivatives and methods of use thereof 里亚塔医药公司 2023-11-07 CN claimed
CN-107108647-A Substituted pyridine compounds having herbicidal activity 巴斯夫欧洲公司 2017-08-29 CN claimed
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US claimed
EP-2049484-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS AstraZeneca AB (SE) 2009-04-22 EP claimed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 WO claimed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US claimed
EP-4676480-A1 INHIBITORS OF DNA POLYMERASE THETA Breakpoint Therapeutics GmbH (DE) 2026-01-14 EP disclosed
WO-2024189493-A1 INHIBITORS OF DNA POLYMERASE THETA BREAKPOINT THERAPEUTICS GMBH (DE) 2024-09-19 WO disclosed
US-20240293401-A1 COMBINATION THERAPY WITH AN LXR AGONIST AND AN INHIBITOR COMPOUND Asteroid Therapeutics (US) 2024-09-05 US disclosed
CN-117730083-A Pyrimidine compounds as MAP4K1 inhibitors 格兰马克专业公司 2024-03-19 CN disclosed
CN-117715642-A Heterocyclic compounds and methods of use 薛定谔公司 2024-03-15 CN disclosed
EP-3827241-B1 DISSOCIATION OF BIOLOGICAL SAMPLES GOLDSBOROUGH ANDREW SIMON (FR) 2024-03-13 EP disclosed
EP-2208729-A1 OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING Research Foundation Itsuu Laboratory (JP) 2010-07-21 EP disclosed
EP-2049484-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS AstraZeneca AB (SE) 2009-04-22 EP disclosed
WO-2009018116-A1 PROCESS FOR FLUORINATION USING 1,1,2,2-TETRAFLUOROETHYL-N,N-DIMETHYLAMINE E. I. DU PONT DE NEMOURS AND COMPANY (US) 2009-02-05 WO disclosed
US-7485693-B2 Primer composition for a fluorinated elastomer or a fluorinated gel SHIN-ETSU CHEMICAL CO., LTD. (JP) 2009-02-03 US disclosed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 WO disclosed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US disclosed